Apellis Pharmaceuticals focuses on creating medicines targeting eye diseases and rare neurological diseases. Read why I rate ...

Viking Holdings (NYSE:VIK) sees premarket drop despite strong Q1 results, with 25% revenue growth and increased bookings ...

Strong Buy with an $81 PT, citing rapid restructuring and operational reset unlocking durable growth. Management's ...

FY2025 results crushed expectations, with strong growth in QCT, IoT, and Automotive segments. Read my analysis.

In the article below I will elaborate on 1 high-yielding REIT to buy and 1 high-yielding REIT to avoid. Apple Hospitality ...

ATI ( NYSE: ATI) late Monday was downgraded to Sector Weight from a previous investment rating of Overweight by analysts at ...

During Q1 2025, the Janus Henderson Growth And Income Managed Account Portfolio returned -4.15% (gross) and the S&P 500® ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Skeptical of the S&P 500 rally? Learn why rising interest rates, high valuations, and economic headwinds signal potential ...

Raymond James downgraded Nutanix (NASDAQ:NTNX) to Market Perform from Outperform with an $83 target price. Shares of Nutanix, ...

The Janus Henderson Growth And Income Fund returned -4.37% and the S&P 500® Index returned -4.27%. Click here to read the ...

Apple's weak sales growth, overvaluation, and rising tariffs impact its profitability and performance against other Big Tech.